Paving the path to better understanding T-cell lymphomas: The importance of lymphoma registries

Despite progresses in the field of non-Hodgkin lymphoma, therapy responses and outcomes remain poor for patients with T-cell lymphoma (TCL), especially for those with relapsed and refractory disease [1,2]. Factors such as marked disease heterogeneity, paucity of cases, and a distinct geographic distribution have limited the field's ability to make substantive and innovative advances. Perhaps, the most significant challenge is the absence of TCL-specific regimens, with CHOP-like chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) remaining as the standard of care for peripheral TCL (PTCL) in spite of high relapse rates [2].

Abstract licence: CC BY-NC

10 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.